EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells

Kyu Sic You iD, Tae-Sung Kim iD, Su Min Back, Jeong-Soo Park, Kangdong Liu iD, Yeon-Sun Seong iD, Dong Joon Kim, Yong Weon Yi iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kyu Sic You und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, Dankook University, Cheonan-si 31116, Republic of Korea. Hauptthemen laut MEDLINE: Janus Kinase 2, Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-akt, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase 2 (JAK2) inhibitors have gained regulatory approval for treating various human diseases. While the JAK2/signal tranducer and activator of transcription 3 (STAT3) pathway plays a role in tumorigenesis, JAK2/STAT3 inhibitors have shown limited therapeutic efficacy in triple-negative breast cancer (TNBC). In this study, we assessed the antiproliferative effects of clinically approved JAK2 inhibitors in TNBC cell lines (MDA-MB-231 and HS578T) using the MTT assay. Among the four JAK2 inhibitors evaluated (fedratinib, cerdulatinib, peficitinib, and filgotinib), fedratinib significantly inhibited the proliferation of TNBC cells with IC50 values below 2 μM. Fedratinib also demonstrated superior efficacy in inhibiting long-term colony formation compared to other JAK2 inhibitors. Western blot analyses showed that fedratinib uniquely inhibits the phosphoinositide 3-kinase (PI3K)/AKT pathway and moderately affects the MAP kinase/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, in addition to targeting JAK2/STAT3 signaling. Moreover, fedratinib distinctly decreased MYC and cyclin D1 protein levels while inducing poly (ADP-ribose) polymerase (PARP) cleavage and apoptotic cell death more effectively than other JAK2 inhibitors. We next investigated the effects of simultaneously inhibiting JAK2/STAT3 together with the MEK/ERK or PI3K/AKT pathways, as well as the impact of triple pathway inhibition. Notably, combining ceduratinib with either cobimetinib (MEK inhibitor) and ipatasertib (AKT inhibitor) or trametinib (MEK inhibitor) and alpelisib (PI3K inhibitor) mimicked the effects of fedratinib on the cell proliferation, MYC and cyclin D1 suppression, and pro-apoptotic protein induction. These finding suggest that JAK2 inhibition enhances the anticancer effects of concurrent MEK/ERK and PI3K/AKT pathway inhibition, while JAK2 inhibition alone shows minimal efficacy in TNBC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Triple Negative Breast NeoplasmsProto-Oncogene Proteins c-aktProtein Kinase InhibitorsHumansCell ProliferationCell Line, TumorFemaleSignal TransductionSTAT3 Transcription FactorMAP Kinase Signaling SystemMitogen-Activated Protein Kinase KinasesApoptosisSulfonamidesPhosphatidylinositol 3-KinasesBenzenesulfonamidesPyrrolidines

Stichwörter der Autor:innen

JAK2/STAT3 pathwayMEK/ERK pathwayPI3K/AKT pathwayanticancercombinationprotein kinase inhibitorstriple-negative breast cancer

Substanzen

Janus Kinase 2Proto-Oncogene Proteins c-aktProtein Kinase InhibitorsJAK2 protein, humanfedratinibSTAT3 Transcription FactorMitogen-Activated Protein Kinase KinasesSulfonamidesPhosphatidylinositol 3-KinasesBenzenesulfonamides

Autor:innen und Institutionen

  • Department of Biochemistry, College of Medicine, Dankook University, Cheonan-si 31116, Republic of Korea.
  • Multidrug-Resistant Refractory Cancer Convergence Research Center (MRCRC), Dankook University, Cheonan-si 31116, Republic of Korea.
  • Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou 450008, China.
  • China-US (Henan) Hormel Cancer Institute, Zhengzhou 450008, China.
  • Department of Microbiology, College of Medicine, Dankook University, Cheonan-si 31116, Republic of Korea.

ORCID-Profile: Kyu Sic You, Tae-Sung Kim, Kangdong Liu, Yeon-Sun Seong, Yong Weon Yi

Förderung

  • National Research Foundation of Korea

Zitieren

APA

You, K. S., Kim, T. S., Back, S. M., Park, J. S., Liu, K., Seong, Y. S., Kim, D. J., & Yi, Y. W. (2025). JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136139

Vancouver

You KS, Kim TS, Back SM, Park JS, Liu K, Seong YS, et al. JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136139

BibTeX
@article{You2025,
  author = {You, Kyu Sic and Kim, Tae-Sung and Back, Su Min and Park, Jeong-Soo and Liu, Kangdong and Seong, Yeon-Sun and Kim, Dong Joon and Yi, Yong Weon},
  title = {JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136139}
}
Kostenlos starten →